Search clinical trials for: Oprozomib

Total 9 results

Amgen

Terminated

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia

United States
Amgen

Completed

Phase 1 Study of Oprozomib Administered Orally in Patients With Advanced Refractory or Recurrent Solid Tumors

Solid Tumors

United States
Amgen

Terminated

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States, France
Amgen

Withdrawn

Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

United States
ViiV Healthcare
GlaxoSmithKline

Terminated

Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects

Infection, Human Immunodeficiency Virus I

United States, Canada, Puerto Rico
Amgen

Terminated

Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Amgen

Completed

A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Greece, Italy, Netherlands
Amgen

Terminated

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

Advanced Non-Central Nervous System (CNS) Malignancies

United States
Amgen

Terminated

A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States

3

Subscribe